Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)

AiViva BioPharma

Status and phase: Active, not recruiting; Phase 1

Conditions: Diabetic Macular Edema; Macular Edema; Neovascular Age-related Macular Degeneration

Treatments: Drug: AIV007

Study type: Interventional

Funder types: Industry

Identifiers

NCT05698329

AIV007-E02

Details and patient eligibility

About

To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).

Full description

AIV007 is a multiple kinase inhibitor of vascular endothelial growth factor receptors (VEGFR 1, -2 & -3); fibroblast growth factor receptors (FGFR-1, -2, -3 & -4); and platelet-derived growth factor receptors (PDGFR-α & β)1. Lenvatinib is the active pharmaceutical ingredient in AIV007 formulation that is FDA-approved for oral administration for patients with advanced renal cell carcinoma (RCC), differentiated thyroid cancer (DTC), unresectable hepatocellular carcinoma (HCC), and advanced endometrial carcinoma (Lenvima USPI 2021; NDA 206947).

AiViva BioPharma, Inc. (AiViva) has developed a novel, thermoresponsive gel suspension of AIV007 for periocular administration to form a durable depot. This monotherapy is in development for the treatment of retinal and choroidal vascular disease (i.e., neovascular age-related macular degeneration (nAMD) & diabetic macular edema (DME)). For preclinical and clinical (AIV007-E02) studies using periocular administration, AIV007 is injected outside the eyeball and the depot forms a soft mass, referred to as posterior juxtascleral depot (PJD) placement.

Enrollment: 19 patients

Sex: All

Ages: 21 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

General inclusion Criteria:

1. Male or female subjects aged 21-90 years (inclusive) at screening
2. BCVA in the study eye at screening and baseline/Day 1: ETDRS letter score ≤ 75 and ≥ 24 (20/32 to 20/330 Snellen equivalent)
3. Subject must have received treatment within the 24 months before screening with intravitreal (IVT) injections of an anti-VEGF agent with the last anti-VEGF injection in the study eye being at least 6 weeks (42 days) before baseline/Day 1.
4. Subject has documentation of anti-VEGF responsiveness
5. Subject must provide written informed consent before any study-related procedures are performed
6. Clear ocular media and adequate pupil dilation in both eyes to permit good-quality photographic imaging

nAMD subject

1. The active CNV is confirmed by FA (evidence of leakage)
2. Residual intraretinal or subretinal fluid based on SD-OCT
3. CST ≥ 300 µm as assessed by SD-OCT
4. Total lesion size < 10 disc areas (25.4 mm2)
5. Absence of geographic atrophy within 200 µm of the fovea
6. If subretinal hemorrhage is present, it must be < 50% of the total CNV lesion and/or not involve the fovea
7. If fibrosis is present, it must be <50% of the total lesion area

DME subject

1. Diagnosis of diabetes mellitus (Type 1 or Type 2)
2. Subject has clinically significant DME with central involvement (CST≥300 μm by OCT)
3. The decrease in vision in the study eye was determined by the investigator to be primarily the result of DME

Exclusion criteria

1. Previous treatment for nAMD or DME in the study eye other than standard-of-care anti-VEGF IVT injection, e.g., cell therapy, brachytherapy, gene therapy
2. Uncontrolled IOP, defined as an IOP > 25 mmHg
3. Poorly controlled diabetes mellitus defined as hemoglobin A1c (HbA1c) >10% at screening visit
4. The spherical equivalent for refractive error in the study eye of worse than 8.0 diopters of myopia (before cataract or refractive surgery) per the current prescription
5. Any history of active bacterial, viral, fungal, or parasitic ocular or periocular infection, or intraocular inflammation in either eye within the 30 days before the screening Visit
6. History of vitreous hemorrhage within 3 months before screening in the study eye
7. Uncontrolled systemic disease or any other condition or therapy that would make the participant unsuitable for the study
8. Participation in any investigational study within 60 days before the screening visit, or planned use of an investigational product or device during the study; any exposure to a prior investigational drug product must be fully washed out (at least 5 half-lives)
9. History of allergy or hypersensitivity to constituents of the study treatment formulation, topical iodine, ocular antimicrobial solutions, or clinically relevant hypersensitivity to fluorescein

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

19 participants in 6 patient groups

AIV007 low dose

Experimental group

Description:

Periocular injection, low dose

Treatment:

Drug: AIV007

AIV007 intermediate dose 1

Experimental group

Description:

Periocular injection, intermediate dose 1

Treatment:

Drug: AIV007

AIV007 intermediate dose 2

Experimental group

Description:

Periocular injection, intermediate dose 2

Treatment:

Drug: AIV007

AIV007 intermediate dose 3

Experimental group

Description:

Periocular injection, intermediate dose 3

Treatment:

Drug: AIV007

AIV007 intermediate dose 4

Experimental group

Description:

Periocular injection, intermediate dose 4

Treatment:

Drug: AIV007

AIV007 High dose

Experimental group

Description:

Periocular injection, high dose

Treatment:

Drug: AIV007